Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia

• Published in: Cancer 2010-01, Vol.116 (1), p.98-105
• Main Authors: Inaba, Hiroto, Stewart, Clinton F., Crews, Kristine R., Yang, Shengping, Pounds, Stanley, Pui, Ching‐Hon, Rubnitz, Jeffrey E., Razzouk, Bassem I., Ribeiro, Raul C.
• Format: Article
• Language: English
• Subjects: acute myeloid leukemia; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Child; Child, Preschool; cladribine; Cladribine - administration & dosage; Cladribine - adverse effects; Cladribine - pharmacokinetics; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematologic and hematopoietic diseases; Humans; Infant; Leukemia, Myeloid, Acute - drug therapy; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Maximum Tolerated Dose; Medical sciences; pediatric; Recurrence; Retreatment; topotecan; Topotecan - administration & dosage; Topotecan - adverse effects; Topotecan - pharmacokinetics; Tumors
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.24712

BACKGROUND: The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed. METHODS: In phase 1 and pilot studies, the authors evaluated the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of a 5‐day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory AML. The cladribine dose was escalated as follows: 9.1, 13.6, 16.3, and 19.5 mg/m2 per day (8.9 mg/m2 per day in the pilot study). Outcome was analyzed according to the absence (Stratum 1) versus presence (Stratum 2) of previous allogeneic hematopoietic stem cell transplantation. Twenty‐six patients (20 in Stratum 1 and 6 in Stratum 2) were treated. RESULTS: The MTD was not reached in Stratum 1, but a DLT occurred at the lowest cladribine dosage (9.1 mg/m2 per day) in Stratum 2. Febrile neutropenia was common in both strata. Nine (34.6%) of 26 patients experienced a complete response, and 7 (30.4%) achieved a partial response; 5 (19.2%) were long‐term survivors at the time of last follow‒up. Clinical outcome was not associated with cladribine or topotecan systemic exposure. CONCLUSIONS: The combination was well tolerated in Sratum 1, and the response rate was encouraging. This regimen offers a postrecurrence treatment alternative for patients, especially those who have received anthracycline‐containing chemotherapy. Cancer 2010. © 2010 American Cancer Society. The authors evaluated the maximum tolerated dose and dose‐limiting toxicities of a 5‐day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory acute myeloid leukemia. This regimen offers a treatment alternative for patients, especially those who have received anthracycline‐containing chemotherapy.